New Findings on Hydroxychloroquine, Denosumab

References

1. Antoniou CK, Dilaveris P, Manolakou P, et al. QT Prolongation and malignant arrhythmia: How serious a problem? Eur Cardiol. 2017;12(2):112–120.
2. Chugh SS, Reinier K, Teodorescu C, et al. Epidemiology of sudden cardiac death: Clinical and research implications. Prog Cardiovasc Dis. 2008 Nov–Dec;51(3):213–228.
3. Chauhan K, Ackerman MJ, Crowson CS, et al. Population-based study of QT interval prolongation in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2015 Jan–Feb;33(1):84–89.
4. Panoulas VF, Toms TE, Douglas KM, et al. Prolonged QTc interval predicts all-cause mortality in patients with rheumatoid arthritis: An association driven by high inflammatory burden. Rheumatology (Oxford). 2014 Jan;53(1):131–137.
5. Nomura A, Kishimoto M, Takahashi O, et al. Prolongation of heart rate-corrected QT interval is a predictor of cardiac autonomic dysfunction in patients with systemic lupus erythematosus. Rheumatol Int. 2014 May;34(5):643–647.
6. McGhie TK, Harvey P, Su J, et al. Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus. Clin Exp Rheumatol. 2018 Jul–Aug;36(4):545–551.
7. Stas P, Faes D, Noyens P. Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine. Int J Cardiol. 2008 Jul 4;127(2):e80–82.
8. O’Laughlin JP, Mehta PH, Wong BC. Life threatening severe QTc prolongation in patient with systemic lupus erythematosus due to hydroxychloroquine. Case Rep Cardiol. 2016;2016:4626279.
9. Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 Sep 1;5(9):1036–1041.
10. Morizio P, Burkhart JI, Ozawa S. Denosumab: A unique perspective on adherence and cost-effectiveness compared with oral bisphosphonates in osteoporosis patients. Ann Pharmacother. 2018 Oct;52(10):1031–1041.
11. Mok CC, Ho LY, Ma KM. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: A 12-month randomized controlled trial. Bone. 2015 Jun;75:222–228.
12. Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: A multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018 Jun;6(6):445–454.